A novel method and composition useful for inhibiting IFG1 based on IGF1 mediated signaling.
IGF1 has been implicated in several aspects of cancer biology. Levels of IGF1 expression are increased in cancers such as breast, lung, and prostate. IGF1 inhibits apoptosis and confers resistance to chemo- and radiation- therapies. Furthermore, high levels of integrin αvβ3, like IGF1, correlate with cancer growth and progression. Traditionally, it has been thought that IGF1 binds to the IGF receptor type 1 (“IGF-IR”) and that integrin αvβ3 binds to extracellular matrix (“EM”) ligands. Based on this prior assumption, IGF1 and IGF-IR have been targets of cancer therapies.
Researchers at the University of California, Davis have discovered a new mechanism for IGF1 signaling. They have found that the interaction between IGF1 and certain integrin molecules is involved in IGF1-mediated signaling. More specifically, integrin αvβ3 has been shown to directly interact with IGF1 and it is this interaction which relates to enhanced cell proliferation and αvβ3’s ability to interact with the EM.
|United States Of America||Issued Patent||8,685,403||04/01/2014||2008-567|